



European Monitoring Centre
for Drugs and Drug Addiction

Session 1: The impact of COVID-19 on the 2020 TDI data and other treatment data collections



Objectives

Discuss the impact of COVID-19 on the 2020 TDI data

Identify factors that may affect or influence the 2020 data

Improve our data analyses and interpretations



What do you expect your national TDI data to look like in 2020 compared to 2019?

Press the link in the chat

Or

1) Go to www.menti.com


2) Enter code: 74 61 13 6



EMCDDA Trendspotter study (May 2020)

FIGURE 6

Preliminary data on the number of all clients and new clients entering treatment between January and March 2020 in four EU countries




Source: Snapshot Treatment Demand Indicator (TDI), April 2020. Data from Bulgaria, Ireland (sentinel centres, only total number of all clients), Lithuania and Portugal.



EMCDDA Trendspotter study (May 2020)

FIGURE 7


Preliminary data on all clients entering treatment by main drug between January and 2020 in four EU countries



Source: Snapshot Treatment Demand Indicator (TDI), April 2020. Data from Bulgaria, Ireland (sentinel centres, only total number of all clients), Lithuania and Port


FIGURE 9

Numbers of face-to-face and phone consultations at the Riga Addiction Medicine Centre, Latvia, in March and April 2020




Source: Inga Landsmane, Riga Addiction Medicine Centre.


Preliminary number of all clients and new clients entering treatment between January and June 2020 in 4 EU countries (BE, HR, SK, LT) - all reporting centres



Preliminary number of new clients entering treatment between January and June 2020 in 4 EU countries (BE, HR, SK, LT) - all reporting centres




Preliminary data - All clients entering treatment by main drug between Jan and June 2020 in 4 EU countries (BE, HR, SK, LT) - all reporting centres




— Opioids — Cocaine — Stimulants other than cocaine — Hypnotics and sedatives
— Hallucinogens — Volatile inhalants — Cannabis — Other substances

Preliminary data - All clients entering treatment by main drug between Jan and June 2020 in 4 EU countries (BE, HR, SK, LT) - all reporting centres



Hypothetical trend for 2020




Possible impact on the 2020 data

- Possibly an overall decrease of 20-40% in entrants (data) across Europe in 2020...

A quick and misleading interpretation when looking at the overall drop in demands would be:

A large number of people did not receive treatment during the pandemic...

Primarily because of disruptions in drug treatment provision



Possible impact on the 2020 data

An actual reduction in demand for treatment?

Closure of centres or disruption of interventions?

Centres are not recording or reporting due to reduced capacity?

Were some providers more affected than others which may explain a certain % of the lower demands (e.g. inpatient centres vs outpatient centres?)



Mentimeter! Have a look at the chat...



Possible impact on the 2020 data

Are we not recording entrants receiving alternative treatment options (e.g. tele-medicine)?

What will the TDI data not show which actually happened in terms of treatment provision outside the TDI recording system (low-threshold OST – compensation effect)?

Were there particular client groups that were under-served compared to 2019 (cannabis? cocaine?)?



Mentimeter! Have a look at the chat...



Possible impact on the 2020 data

During which periods (lockdown, easing, 2nd wave) are the above phenomena observed or more prominent?



Mentimeter! Have a look at the chat...





European Monitoring Centre
for Drugs and Drug Addiction

